Q-omics provides the consensus-scored OSCP1 profile across patient tissues and cancer cell-line models. OSCP1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, OSCP1 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, OSCP1 RNA expression shows 18,692 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, KICH, and ACC as cancer lineages where OSCP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OSCP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OSCP1 survival associations across molecular data types. OSCP1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OSCP1 RNA expression–survival associations across cancer types. High OSCP1 expression shows unfavorable associations in BLCA, LGG and KICH, but favorable associations in KIRP, KIRC and MESO. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify KIRP as the clearest survival context for OSCP1 RNA expression.
This table summarizes OSCP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for OSCP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OSCP1 shows lower tumor expression in KICH, THCA, LUAD, LUSC and KIRC and higher tumor expression in LIHC. The KICH box plot shows higher OSCP1 RNA expression in normal versus tumor tissue (log2 FC = −2.218, t-test p < 0.001).
This table shows molecular features associated with OSCP1 in patient tissues and cancer cell lines. In patient samples, OSCP1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, OSCP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
